GlassScriptPhysician profile
Danielle Mekahel
NPI 1205329000
$2,410.04
in general payments reported to CMS, 2019-2025
15 companies · $719 in 2025
The $719 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2023: $303 · 2024: $1,024 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.45 | 2023-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $361.07 | 2023-2025 | Mounjaro, Zepbound |
| Exeltis, USA INC. | $343.98 | 2023-2025 | Slynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.05 | 2023-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $265.48 | 2024-2025 | Myfembree |
| Abbott Laboratories | $159.66 | 2021 | |
| Amgen INC. | $143.35 | 2024-2025 | Evenity, Prolia, Repatha |
| Nevro Corp. | $126.24 | 2021 | |
| Boston Scientific Corporation | $69.35 | 2021 | |
| Radius Health, INC. | $59.64 | 2024 | |
| Myriad Women'S Health, INC. | $48.25 | 2023 | Myrisk |
| Becton, Dickinson and Company | $21.59 | 2024 | Bd Onclarity |
| Millicent US INC | $15.60 | 2025 | Femlyv, Intrarosa |
| Pfizer INC. | $13.96 | 2024 | |
| Orthofix Medical, INC. | $9.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mekahel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.